The University of Chicago Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Salgia, Ravi
One or more keywords matched the following items that are connected to Salgia, Ravi
Item TypeName
Concept Receptor Protein-Tyrosine Kinases
Academic Article Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.
Academic Article Role of receptor tyrosine kinases in lung cancer.
Academic Article Receptor tyrosine kinases and inhibitors in lung cancer.
Academic Article Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
Academic Article Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
Academic Article Differential expression of RON in small and non-small cell lung cancers.
Academic Article Therapeutic targeting of receptor tyrosine kinases in lung cancer.
Academic Article Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Academic Article Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.
Academic Article Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
Academic Article Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
Academic Article Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.
Academic Article Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer.
Academic Article Novel targets for therapeutic agents in small cell lung cancer.
Academic Article RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Academic Article Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
Academic Article A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
Academic Article Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
Academic Article Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression.
Academic Article Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
Academic Article Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer.
Academic Article Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
Academic Article AXL mediates resistance to cetuximab therapy.
Academic Article A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
Academic Article AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
Academic Article C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype.
Academic Article Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
Academic Article Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.
Academic Article Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Academic Article RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
Academic Article The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
Academic Article The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
Academic Article AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.
Academic Article AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer.
Search Criteria
  • Endothelial Protein C Receptor